Antivirals against the Chikungunya Virus

Area of Science:

• Virology and Infectious Diseases
• Drug Discovery and Development

Background:

• Chikungunya virus (CHIKV) is an alphavirus causing significant global epidemics.
• CHIKV infection results in chikungunya fever (CHIKF), characterized by severe joint pain and myalgia.
• The absence of approved antiviral drugs or vaccines necessitates urgent therapeutic development.

Purpose of the Study:

• To provide a comprehensive review of current antiviral research focused on small-molecule inhibitors against CHIKV.
• To highlight diverse strategies employed in identifying potential CHIKV-inhibiting compounds.
• To discuss promising viral and host targets for therapeutic intervention.

Main Methods:

• Literature review of published research on CHIKV antiviral drug discovery.
• Analysis of various approaches for identifying small-molecule inhibitors.
• Evaluation of identified viral and host targets for their therapeutic potential.

Main Results:

• Several small-molecule inhibitors targeting CHIKV have been identified through various screening and design strategies.
• Both viral targets (e.g., viral enzymes) and host factors essential for CHIKV replication are being explored.
• Promising compounds and targets are discussed, indicating progress in the field.

Conclusions:

• The development of effective small-molecule inhibitors is critical for treating chikungunya fever (CHIKF).
• Continued research into novel viral and host targets is essential for advancing CHIKV therapeutics.
• This review consolidates current knowledge to guide future drug development efforts against CHIKV.